close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

29.45 +0.09 (+0.31%)
Official Closing Price Updated: 4:10 PM EST, Nov 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs ↗
Biotech and pharma stocks, tracked by the iShares Biotechnology ETF, have shown relative strength amid the tech sell-off, with Eli Lilly and Pfizer standing out as top performers. 
Via MarketBeat
Topics Artificial Intelligence ETFs
News headline image
Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice ↗
This company made headlines with its coronavirus vaccine. 
Via The Motley Fool
News headline image
A Look Back at Generic Pharmaceuticals Stocks’ Q2 Earnings: Viatris (NASDAQ:VTRS) Vs The Rest Of The Pack
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how generic pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Most Active S&P 500 Stocks in Today's Session ↗
Via Chartmill
Topics Stocks
News headline image
Pfizer's Stock Is Finally Showing Signs of Life. Could This Be the Start of a Much Bigger Rally? ↗
The stock has outperformed the market this year, and it still looks heavily undervalued. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy? ↗
It has been a volatile year for the biotech. 
Via The Motley Fool
News headline image
Warren Buffett's Market Warning Is Hard to Ignore. But I'd Buy These 3 Stocks Anyway. ↗
Not every company is at risk. 
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
Here's What $10,000 in Each of These 5 High-Yield Dividend Stocks Could Pay You in a Year ↗
These five high-yield dividend stocks are paying yields of 5.88% to 16.72% -- but beware of a few key risks. 
Via The Motley Fool
News headline image
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead? ↗
The gene-editing biotech stock is down more than 12% this year. 
Via The Motley Fool
Topics ETFs Lawsuit
News headline image
Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline ↗
BioNTech has billions in cash, and its oncology programs are moving into late-stage clinical trials. 
Via The Motley Fool
News headline image
Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends ↗
You'd need to invest over $200,000 in the pharma leader at its current price. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe? ↗
Pfizer's dividend yield is attractive, but investors need to know if it can maintain it. 
Via The Motley Fool
Topics Intellectual Property
Most-Active S&P 500 Stocks in Oct. 16, 2026 US Session ↗
Via Chartmill
Topics Stocks
News headline image
6 Blue Chip Stocks Trading Well Below Their Highs ↗
Some look like bargains, but others could be value traps. 
Via The Motley Fool
News headline image
2 High-Yield Dividend Stocks Worth Buying Before 2026 Ends ↗
Verizon and Pfizer pay generous dividends, and each has a different path to growth. Here's how income investors can lock in yield before year-end. 
Via The Motley Fool
News headline image
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗
AbbVie is raising its outlook with Skyrizi and Rinvoq offsetting Humira losses. Pfizer is rebuilding its pipeline around obesity drugs and key readouts expected over the next year. 
Via The Motley Fool
Topics Intellectual Property
Most active S&P500 stocks in Wednesday's session ↗
Via Chartmill
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
Forget Treasury Bonds: This 6%-Yielding Pharma Stock Pays You to Wait for Its Pipeline ↗
A reliable payout, a growing cancer treatment lineup, and improving guidance make this drugmaker worth a second look right now. 
Via The Motley Fool
Topics Bonds
News headline image
Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026
From Pfizer Inc.
Via Business Wire
News headline image
Branded Pharmaceuticals Stocks Q2 In Review: Zoetis (NYSE:ZTS) Vs Peers
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking a... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗
Johnson & Johnson trades at a higher valuation with growing sales, while Pfizer's dividend yield is near 6% as patents expire from 2026 through 2030. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Better Invesco Healthcare ETF: PJP Targeting Pharmaceuticals vs. RSPH's Broader Sector Lens ↗
PJP's one-year return beats RSPH's, but RSPH offers broader diversification across 61 healthcare holdings at a lower expense ratio. 
Via The Motley Fool
Topics ETFs
News headline image
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? ↗
You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Better Pharma ETF: iShares IHE vs. State Street XPH ↗
IHE concentrates 23.6% in Eli Lilly and delivers 1.4% yield, while XPH spreads risk across 62 holdings with a lower 0.35% expense ratio. 
Via The Motley Fool
Topics ETFs
News headline image
Alnylam vs. Ionis: Here's the Better Bad-News Buy ↗
The sell-offs for both of these beaten-down biotech stocks appear to be overdone. 
Via The Motley Fool
News headline image
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗
Both face patent cliffs and regulatory headwinds, but their balance sheets and cash generation tell starkly different stories. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Growth Stocks to Buy in October ↗
Grail and Veeva Systems could be well insulated from near-term headwinds. 
Via The Motley Fool
News headline image
Pfizer Trades Under 10 Times Forward Earnings With a Yield Near 6%. Here's What History Says Happens Next. ↗
Pfizer is deeply unloved, and for good reason, but don't count this drug maker out just yet. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Avident Health and Unite for HER Awarded Quality Improvement Grant from Pfizer and the National Comprehensive Cancer Network® (NCCN®) to Support Metastatic Breast Cancer Patients
October 8, 2026 -- Initiative leverages the MyNavigator™ digital care coordination platform to translate NCCN Guidelines® into actionable home-based education, expand access to integrative oncology... 
Via 24-7 Press Release
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.